Ivo Claassen | Head of Veterinary Medicines Division
EMA

Ivo Claassen is the head of Veterinary Medicines Division at the European Medicines Agency. He has over 35 years of experience in multiple roles in vaccine production, QC/QA, R&D and regulatory affairs, both for human and veterinary medicinal products. He has worked internationally on capacity building for veterinary infectious disease management, including laboratory diagnosis, vaccine production and field trials

Appearances:

Day 1 - Tuesday 14th October @ 16:00

From Farm to Fish: Species-Specific Strategies to Reduce Antibiotic Use in Livestock and Aquaculture

The role of combination vaccines and new vaccine platforms in preventing bacterial infections
Case studies of successful vaccine interventions that led to measurable reductions in antibiotic use.
Management and biosecurity strategies: recent progress in biosecurity protocols and livestock management practices
Global standards and coordination efforts for AMR control in livestock.
Species specific approaches: poultry, swine, aquaculture
New vaccine platforms and combination approaches in veterinary health
Biosecurity protocols and best practices for AMR control

Moderator: Jan Poolman, Executive Advisor & Founder, CreaBacVac B.V.

David Farcas, Director, Chile, Yelcho

Ivo Claassen, Head of Veterinary Medicines Division, EMA

Day 2 - Wednesday 15th October @ 09:00

Keynote Panel: Rethinking Global Health Threats and Responses: H5N1, Mpox, Measles, Marburg, Climate, Zoonoses, and Emerging Risks

Pandemic vs. endemic priorities: What’s missing from the global agenda? – Are we too fixated on future pandemics while ignoring the growing threats of endemic infectious diseases (e.g., TB, dengue, H5N1)?
Climate-driven disease risks: Are we accurately predicting which pathogens will surge due to climate change? (e.g., vector-borne diseases like malaria vs. less-discussed threats). How can we better anticipate less obvious threats?
How should we be investing in surveillance and R&D? – What innovations (AI, genomics, forecasting) actually have the potential to get ahead of the next crisis?
How do we ensure that disease prioritisation is driven by science, not politics? – What structural and policy shifts are needed to avoid repeating past mistakes?
Are we adequately investing in diagnostic capabilities for future threats, or are we overly focused on vaccines and treatments? How can improved diagnostic strategies enhance our ability to detect and respond to emerging threats quickly?
How can we improve international collaboration in disease surveillance, research, and response while addressing geopolitical challenges and ensuring equitable access to resources?

Wolfgang Philipp, Principal Adviser, Chief Science Officer, European Commission Health Emergency Preparedness & Response (HERA)

Maria Elena Bottazzi, Co-Director of Texas Children's Hospital Center for Vaccine Development, Baylor College of Medicine